Evotec and Celgene further expand iPSC collaboration

06-Jun-2019 - Germany

Evotec SE announced that its strategic alliance with Celgene Corporation (“Celgene”) has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec.

Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Since then, the companies have achieved several milestones including advancement of one programme into lead optimisation as well as including additional cell lines and now a new cell type. Currently approved drugs only offer short-term management of the patients’ symptoms and there is a huge unmet medical need for therapeutic modalities that slow down or reverse disease progression in the field of neurodegenerative diseases. The collaboration pursues an innovative approach to the discovery and development of novel medicines by leveraging Evotec’s unique human iPSC technology platform.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “Patients suffering from neurodegenerative diseases today have limited treatment options, the majority of which only support the management of symptoms but do not address the cause of their disease. With our iPSC platform and Celgene’s expertise, we feel confident to provide physicians with additional treatment options in the future and to deliver disease-modifying treatments to patients.”

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...